Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Vivo UVA Sunscreen Tests "Clinically Irrelevant...Unethical" - Diffey

This article was originally published in The Tan Sheet

Executive Summary

The use of in vivo methods for UVA sunscreen testing is "clinically irrelevant" and "unethical," Brian Diffey, PhD, Newcastle General Hospital, maintained at the American Association of Dermatology UVA consensus conference in Washington, D.C. Feb. 4.

You may also be interested in...



UVA Protection Provided By 10% Of Sunscreens Tested - Researcher Diffey

Only six of 59 commercially available sunscreens met the critical wavelength standard of +/-370 nm to establish efficacy against UVA light, Brian Diffey, Newcastle General Hospital, England, et al., determine in a study published in the December Journal of the American Academy of Dermatology.

UVA Protection Provided By 10% Of Sunscreens Tested - Researcher Diffey

Only six of 59 commercially available sunscreens met the critical wavelength standard of +/-370 nm to establish efficacy against UVA light, Brian Diffey, Newcastle General Hospital, England, et al., determine in a study published in the December Journal of the American Academy of Dermatology.

UVA Protection Provided By 10% Of Sunscreens Tested - Researcher Diffey

Only six of 59 commercially available sunscreens met the critical wavelength standard of +/-370 nm to establish efficacy against UVA light, Brian Diffey, Newcastle General Hospital, England, et al., determine in a study published in the December Journal of the American Academy of Dermatology.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel